In connection with the CETSA platform, the BellBrook Labs, LLC states:
“BellBrook Labs wishes to acknowledge the validity of Pelago Biosciences patented and trademarked CETSA technology (US Pat. Nos. 8,969,014; 9,523,963; and 9,528,996) and the use of the Cellular Thermal Shift Assay (CETSA) process described in the patents in relation to the following patent application: WO/2022/174012 (PCT/US2022/016073).”
Michael Dabrowski, CEO of Pelago Bioscience, comments on the announcement;
“We are excited that BellBrook Labs found the CETSA technology to be a useful method for quantifying drug Target Engagement. We are grateful for BellBrook Labs’ acknowledgement of our patented and trademarked technology and we welcome other investigators and those involved in the drug discovery community to engage with us to explore how we can enhance their discovery efforts with the use of our CETSA technology platform and derived services.”
Stockholm, 3 July 2024